Idrabiotaparinux sodium

Drug Profile

Idrabiotaparinux sodium

Alternative Names: Biotinylated idraparinux; SSR 126517; SSR126517E

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Anticoagulants; Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Discontinued Deep vein thrombosis; Embolism

Most Recent Events

  • 11 Dec 2008 Efficacy data from the phase III EQUINOX trial in Deep vein thrombosis presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) (ADNM)
  • 03 Sep 2008 Pharmacodynamics data from a clinical trial in Thrombosis presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top